bmG21

The project:

The project’s main objective focuses on the development of new biomaterials for the effective and controlled delivery and release of therapeutic substances in target organs and tissues, after administration by different routes. To this end, the aim is to develop new in vitro and in vivo models to study drug-delivery and controlled drug-release processes, with an emphasis on crossing physiological barriers. In addition, new image-tracked anti-inflammatory agents will be studied as model therapeutic substances for the study of effectiveness in controlled drug-release processes, together with the delivery and release of genetic material.

CIDETEC’S role in the project:

The work carried out at CIDETEC is focused on the synthesis and characterisation of nanomaterials for cell tracking studies, all directed towards the development of innovative therapies for diseases of high incidence and impact on our society’s social and health system. The new nanomaterials will be based on the different drug delivery systems developed and patented by CIDETEC; single-chain nanoparticles, nanoemulsions and polyplexes, loaded with different active molecules (anti-inflammatory and non-viral vectors) for their delivery and release in different target organs.